Rheumatoid Arthritis
David Liew drdavidliew
11 months 1 week ago
Effective RA therapy is about more than just joints
🇪🇸 RA cohort
TNFi for first 24w led to:
Lean mass index i.e. muscle going up
Fat mass index i.e. fat trending down
Muscle & fat composition are important
Systemic Rx can deliver systemic benefits
#ACR24 ABST1348 @RheumNow https://t.co/mZjcHwxMgW
David Liew drdavidliew
11 months 1 week ago
Steroids in checkpoint inhibitor rheumatic irAEs need to be approached with caution.
Persistent higher doses earlier on might dampen ICI response.
@HSpecialSurgery ICI-IA (inflamm arthritis) cohort
big diff in survival based on early steroid exposure
#ACR24 ABST1989 @RheumNow https://t.co/3WAZ3ZLbFw
David Liew drdavidliew
11 months 1 week ago
Dentition is important in RA, but it's easy to forget it's a matter of life or death.
NHANES data shows fewer teeth strongly correlates with higher mortality (esp cardiovascular).
Missing teeth = CV death HR >30
Holistic dentition is holistic RA care
#ACR24 ABST1325 @RheumNow https://t.co/Z40bSFybuS
David Liew drdavidliew
11 months 1 week ago
Rheumatic irAEs can get on the CAR-T bandwagon, too!
CAR-T can invoke new rheumatological issues (not just cytokine release) - see @DrGomezPuerta's experience.
Infrequent, but if CAR-T in general becomes common, yet another job for us to attend to...
#ACR24 ABST2004 @RheumNow https://t.co/xBSlhUdkNr
David Liew drdavidliew
11 months 1 week ago
Active early RA accentuates regional MSK pain.
Non-articular pain:
easy to ignore & focus on active RA
yes, some is related to RA dx activity
BUT actually it becomes a bigger issue over time
Worth identifying to:
clarify what isn't RA
Rx appropriately
#ACR24 ABST1335 @RheumNow https://t.co/iN5rsyr7Bx
David Liew drdavidliew
11 months 1 week ago
Here's a meta-analysis of MACE/malignancy in JAKi vs TNFi in observational cohort studies.
All the epidemiological challenges here aside, it's a good reminder that with ORAL Surveillance it's *cardiovascular risk enriched pts* we're concerned about.
#ACR24 ABST2264 @RheumNow https://t.co/vIXlrI3V2d
Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty.
With the advent of FDA-approved anti-obesity medications such as semaglutide and tirzepatide, a new avenue for managing this challenging patient population has emerged. But how might these drugs impact the trajectory of RA, and are we on the cusp of a paradigm shift?
Richard Conway RichardPAConway
11 months 1 week ago
My ramblings on the SELECT-GCA study and predictions of the place of upadacitinib in clinical practice in GCA are up now on RheumNow #ACR24 @RheumNow https://t.co/DR5VgVmdse
Richard Conway RichardPAConway
11 months 1 week ago
I've shared some further thoughts on @jeffsparks SAIL-RA study and its finding of the strong association of RA-ILD with disease activity in early RA. And of course couldn't resist going on a tangent about the ACR ILD guidelines! #ACR24 @RheumNow https://t.co/UUDbWw38Im
Richard Conway RichardPAConway
11 months 1 week ago
A key practice changing study (I hope) from #ACR24 has been the preCARA study. Fertility increases with aggressive disease control. My video on this study is up now on @RheumNow https://t.co/Pf3rdTHbOJ
Dr. John Cush RheumNow
11 months 1 week ago
RheumNow Day 2 Recap: ACR Convergence 2024 Highlights https://t.co/YAwOEaNsWs
Janet Pope Janetbirdope
11 months 1 week ago
To stop tsDMARD / bDMARD To improve #COVIDVACCINE response in those w several previous #COVID19 #vaccinations is NOT necessary
This will change my practice!
#ACR24 @RheumNow @ACRheum https://t.co/WXeqMOEfuA


Poster Hall